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Here, we demonstrate that electroporation-enhanced immunization with a rationally designed
HPV DNA vaccine (GX-188E), preferentially targeting HPV antigens to dendritic cells, elicits a
signiﬁcant E6/E7-speciﬁc IFN-g-producing T-cell response in all nine cervical intraepithelial
neoplasia 3 (CIN3) patients. Importantly, eight out of nine patients exhibit an enhanced
polyfunctional HPV-speciﬁc CD8 T-cell response as shown by an increase in cytolytic activity,
proliferative capacity and secretion of effector molecules. Notably, seven out of nine patients
display complete regression of their lesions and viral clearance within 36 weeks of follow up.
GX-188E administration does not elicit serious vaccine-associated adverse events at all
administered doses. These ﬁndings indicate that the magnitude of systemic polyfunctional
CD8 T-cell response is the main contributing factor for histological, cytological and virological
responses, providing valuable insights into the design of therapeutic vaccines for effectively
treating persistent infections and cancers in humans.
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C
ervical cancer is one of the leading causes of cancer death
in women worldwide1,2, and about 75% of its cases are
caused by persistent infection with the most common
high-risk human papilloma virus (HPV) types, namely HPV16
and HPV18 (refs 3,4). HPV persistence is usually associated with
the lack of demonstrable HPV-speciﬁc T-cell immunity, and the
virus-speciﬁc T cells found in pre-malignant and malignant
patients are reported to be generally dysfunctional and sometimes
even suppressive5,6. These ﬁndings suggest that the functional
impairment of virus-speciﬁc T cells is a contributing factor for the
emergence of HPV-induced cervical cancer.
The pre-malignant cervical intraepithelial neoplasia 2 and 3
(CIN2/3), in particular those positive for HPV16, are considered
as high-grade lesions that have approximately a 30% chance of
developing into invasive cancer7. Current treatment for CIN2/3 is
limited to surgical excision, which is associated with about 10%
recurrence rate and pregnancy-related complications, such as
preterm delivery, low birth weight and premature rupture of
membrane8. Recently introduced prophylactic HPV vaccines
(Gardasil and Cervarix) have been shown to be effective in
preventing HPV infection9, but without any therapeutic efﬁcacy
against pre-existing HPV infection or pre-malignant lesions.
Therefore, there is an urgent need for an effective therapeutic
vaccine that can eradicate HPV-related neoplasia without surgical
manipulation.
HPV E6 and E7 act as viral oncoproteins by binding and
promoting degradation of tumour suppressor proteins, p53 and
retinoblastoma (pRb), respectively10. These viral oncoproteins are
an ideal set of targets for a therapeutic vaccine against CIN2/3 and
cervical cancer because these proteins not only induce
tumorigenesis but also are constitutively expressed in HPV-
infected pre-malignant and malignant cells10. Since the regression
of cervical lesions is associated with the presence of a cellular, but
not humoral immune response11,12, a therapeutic vaccine capable
of selectively inducing robust E6/E7-speciﬁc T-cell immunity is
highly desirable. Several attempts at this feat are currently
underway with a varying level of success. Subcutaneous
immunization with a recombinant vaccinia virus-expressing E6/
E7 with interleukin-2 (IL-2) induced the regression of cervical
lesions and cleared HPV infection in 10 out of 21 CIN2/3
patients13. Intrauterus immunization with another recombinant
vaccinia virus-expressing bovine papilloma virus E2 elicited the
regression of high-grade lesions in 19 out of 34 patients14.
Unfortunately, none of these clinical studies presented whether the
vaccine could induce a relevant T-cell immunity and elucidated the
mechanistic explanation behind the observed therapeutic effect.
Induction of an HPV-speciﬁc T-cell response was observed
with other vaccines, but without any meaningful clinical efﬁcacy
for the treatment of high-grade cervical lesions. One study found
that subcutaneous immunization with an HPV16 E6/E7 synthetic
long-peptide vaccine induced detectable level of HPV-speciﬁc
interferon-g (IFN-g)-producing T-cell response in all ﬁve patients
with high-grade cervical dysplasia, but without any reduction in
HPV DNA and histological improvement of the cervical
lesions15. This study resembles the past ﬁnding with
intramuscular injections of an E6/E7 fusion protein mixed
together with ISCOMATRIX adjuvant, which induced IFN-g
enzyme-linked immunospot (ELISPOT) responses in ﬁve out of
15 patients, but without any regression of the cervical lesions16. In
clinical trials with DNA vaccines, intramuscular administration of
an E7 DNA vaccine co-expressing HSP70 as a genetic adjuvant
revealed measurable T-cell response in eight out of 15 patients
with CIN2/3, although a histological regression was shown only
in three out of nine patients17. In a recent study, E6/E7 DNA
vaccine delivered via electroporation (EP) induced a signiﬁcant
HPV-speciﬁc IFN-g-producing T-cell response in 14 out of 18
subjects, but the clinical response could not be examined because
the enroled subjects had their cervical lesions surgically removed
before vaccination18. In case of HPV-associated lower genital
epidermal lesions, vaccination with a synthetic long-peptide
vaccine induced T-cell response in all subjects and exhibited 47%
of complete response rate in patients with vulvar intraepithelial
neoplasia 3 (ref. 19). In essence, a highly effective therapeutic
HPV vaccine that could induce more potent anti-HPV T-cell
response and complete regression of high-grade lesions is yet to
be clearly demonstrated in HPV-associated cervical neoplasia.
Here, we describe a newly developed HPV E6/E7 DNA
therapeutic vaccine, designated GX-188, designed to facilitate the
processing and presentation of HPV E6/E7 antigens by dendritic
cells (DCs) through the co-expression of Fms-like tyrosine
kinase-3 ligand (Flt3L). Vaccination with GX-188 by EP (GX-
188E) elicits a signiﬁcant E6/E7-speciﬁc T helper (Th) 1-polarized
cellular immune response in all nine patients with CIN3.
Importantly, GX-188E vaccination signiﬁcantly induces poly-
functional HPV16-speciﬁc CD8 T-cell response in seven out of
nine patients, which correlates with HPV clearance and complete
resolution of high-grade cervical lesions on cytology and
histology. Therefore, we offer an effective therapeutic vaccine
strategy for eradicating persistent HPV infections and HPV-
induced tumours, together with an important insight into the
immune correlates to control persistent viral infection.
Results
GX-188E vaccination is safe and well tolerated. GX-188 DNA
vaccine is engineered to express E6 and E7 proteins of HPV16
and HPV18 fused to extracellular domain of Flt3L and the signal
sequence of tissue plasminogen activator (tpa); the purpose for
inclusion of Flt3L and tpa is to promote antigen presentation and
trafﬁcking of the fused protein to the secretory pathway,
respectively (Fig. 1a). The activity of tpa is evident, as the GX-
188-induced E6/E7 fusion protein was detected only in the
cytoplasmic compartment of transfected cells, whereas E7 protein
expressed by the same vector without tpa was found in both
cytoplasmic and nuclear compartments (Supplementary Fig. 1a).
The arrangement of HPV E6 and E7 genes in GX-188 was
intentionally shufﬂed, by alternatively placing the amino (N-) and
carboxyl-terminal (C-terminal) domains of the two genes, but
with an overlapping region of 16 amino acids to minimize the loss
of potential T cell-recognizing epitopes at the junction sites
(Fig. 1a). The gene shufﬂing was done to prevent the homo-
dimerization of E6 and E7 regions of the fusion protein, which is
crucial for their binding and degradation of p53 and pRb tumor
suppressor proteins20,21. As expected, the E6/E7 fusion protein
generated by GX-188 DNA vaccine was unable to degrade p53
and pRb proteins, whereas wild-type E6 and E7 proteins induced
their degradation (Supplementary Fig. 1b,c).
According to the inclusion and exclusion criteria for this study,
nine out of 11 screened patients with CIN3 were enroled
(Table 1). The screened patients were examined by multiple
methods, including colposcopy, cytology, histology and HPV type
test, at the visit for screening (VS) time point, 2 weeks before the
start of the trial. All participating subjects received three
injections of GX-188E, with the last two injections given at 4
and 12 weeks after the ﬁrst injection (Fig. 1b).
A total of 49 adverse events (AEs) were recorded during all
visits. Twenty-three AEs, including eczema, ecchymosis, vaginal
itching, sleepiness, anorexia and dizziness were determined to be
unrelated to the vaccination. Nineteen AEs including chills,
injection site pain, swelling and hypoaesthesia, were recorded to
be associated with GX-188E vaccination (Supplementary Table 1).
Although the cause of the remaining seven AEs, including
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headache, rhinitis and fatigue, were unknown, they could be
potentially associated with GX-188E vaccination. However, all
these AEs were considered to be mild (grade 1) and all patients
recovered completely within 3 days after GX-188E vaccination.
Since neither severe AEs nor laboratory abnormalities were
observed at any given dose (Supplementary Tables 1 and 2), the
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Figure 1 | Diagram of GX-188 DNA vaccine and a schematic outline of the clinical trial. (a) GX-188 vaccine was constructed by inserting shufﬂed
overlapping N- and C-terminal domains of E6 and E7 genes of HPV16 and HPV18 types into the pGX27 vector. The E6 and E7 domains are preceded by the
secretory signal sequence of tpa and the extracellular domain of Flt3L. The inserted viral domains are abbreviated according to the HPV strain, the gene,
and the domain; for example, 16E6N represents N-terminal domain of HPV16 E6. ColE1, ColE1-type bacterial origin of replication; gIVS, rabbit b-globin
intervening sequence; KanR, kanamycin resistance gene; MCS, multi-cloning site; pCMV, cytomegalovirus early enhancer/promoter; SV40 poly A, Simian
virus 40 late polyadenylation sequence; SV40 enhancer, Simian virus 40 enhancer. The numbers above each gene segment indicate the corresponding
amino acid sequence. (b) The clinical trial had three periods: Screening of the recruited patients, treatment by three injections of the vaccine, and follow-up
monitoring of the patients. Patients made visits for screening (VS), treatment (VT) and follow-up monitoring (VF) to the clinic during these three periods at
the indicated time points to be examined and/or to receive vaccination.
Table 1 | Baseline characteristics of the patients.
Group Patient no. Age at enrolment (years) HLA type Lesion grade
HLA-A HLA-DRB1
1mg cohort A01 44 *02:06, *30:01 *04:03, *07:01 CIN3, severe dysplasia
A02 30 *02:06, *02:07 *08:03, *14:07 CIN3, severe dysplasia
A03 44 *02:01 *01:01, *04:05 CIN3, carcinoma in situ
2mg cohort A04 37 *26:02, *30:01 *09:01, *16:02 CIN3, carcinoma in situ
A05 23 *02:01, *30:01 *08:03, *13:01 CIN3, severe dysplasia
A06 25 *02:01, *24:02 *01:01, *09:01 CIN3, severe dysplasia
4mg cohort A07 28 *24:02, *26:02 *09:01, *14:06 CIN3, severe dysplasia
A08 23 *02:01, *24:02 *04:06, *15:01 CIN3, severe dysplasia
A09 30 *24:02, *26:01 *08:03, *15:02 CIN3, carcinoma in situ
CIN3, cervical intraepithelial neoplasia 3; HLA, human leukocyte antigen.
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dose of GX-188E was elevated from 1 to 2mg, and then to 4mg
(three patients at each dose) without the enrolment of additional
three subjects at each dose level according to 3þ 3 dose-escalation
design of this clinical trial protocol.
Since it was reported that the administration of Flt3L protein
could increase the frequency of white blood cells (WBCs)22,23, we
measured the number of WBCs and the level of Flt3L in the
blood. A change in the number of WBCs was not observed
(Supplementary Table 2), which is likely due to no signiﬁcant
upregulation of Flt3L level in the blood on GX-188E vaccination
(Supplementary Table 3). Such a ﬁnding is in line with previous
reports with incorporated genetic adjuvants in DNA vaccines,
such as cytokines and HSP70 (refs 17,24–26), implicating that the
use of genetic adjuvants in a DNA vaccine is not usually
associated with severe AEs.
To determine the immunological safety of our approach, we
investigated whether the enhanced delivery of GX-188E generated
anti-DNA antibodies, which are known to be associated with
autoimmune disorders26. The level of antibodies against DNA in
the blood of patients with CIN3 was below the detection limit
(Supplementary Table 4), which is comparable to the previous
results obtained from subjects immunized with DNA vaccine
without EP27,28. Taken together, these results indicate that the
incorporation of EP and genetic adjuvants is relatively tolerable in
clinical trials of DNA vaccines and shows very similar safety
proﬁles observed with the administration of a basic DNA vaccine
without EP.
GX-188E vaccination induces strong cellular immunity. To
study the cellular immune response induced by GX-188E, an
IFN-g ELISPOT assay as described in the Methods was per-
formed before, at VS time point ( 2 weeks), during, at VT2 (2
weeks) and VT4 time points (8 weeks), and after, at VF1 (20
weeks) and VF2 time points (36 weeks), GX-188E vaccination.
Relatively high pre-existing IFN-g ELISPOT response was
detected in one patient (A03), whereas the other eight patients
displayed weak pre-existing HPV-speciﬁc cellular immunity
before vaccination. On the basis of the criteria described in the
Methods, all subjects exhibited a marked increase in the vaccine-
induced E6- and E7-speciﬁc IFN-g ELISPOT response compared
with the background level before vaccination (Fig. 2). Interest-
ingly, two out of nine patients (A06 and A08) developed a con-
siderably enhanced IFN-g response even after a single
immunization (VT2), and additional ﬁve patients (A02, A04,
A05, A07, and A09) exhibited such an elevated response after two
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Figure 2 | GX-188E vaccination induced signiﬁcant HPV16 and HPV18 E6/E7-speciﬁc IFN-c responses. Patients’ PBMCs were harvested and
cryopreserved before (VS), during (VT2, VT4) and after (VF1, VF2) vaccination with GX-188E in all patients. The number of HPV16/18 E6- and E7-speciﬁc
IFN-g secreting cells in PBMCs was determined individually by IFN-g ELISPOT assays after stimulation with HPV16 or HPV18 E6 and E7 peptide pools for
48 h at indicated time points in the 1 (a), 2 (b) and 4mg (c) cohorts. Shown are the average spot-forming units (SFU) per 106 PBMCs in triplicate wells
against each antigen after subtracting the background number of spots (5.7±2.2). Error bars represent s.d. The percentage of E6-speciﬁc response in total
number of spots was 76.6% (A01), 69.3% (A02), 88.9% (A03), 89.2% (A04), 69.1% (A05), 89.4% (A06), 84.2% (A07), 75.1% (A08) and 70.1% (A09)
at VF1. The HPV types found in each patient are indicated in the parentheses. ND, not determined.
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vaccinations (VT4). The remaining two patients (A01 and A03)
in the 1-mg dose group displayed an increased IFN-g response
after three shots of the GX-188E vaccine (VF1). Taken together,
these results suggest that vaccine-induced cellular immune
responses became progressively stronger in all patients during
GX-188E vaccination. In particular, patient A08 exhibited the
highest magnitude of IFN-g ELISPOT response with reactivity up
to 3,500 spot-forming unit per 106 peripheral blood mononuclear
cells (PBMCs). Interestingly, the response against the E6 antigen
was more vigorous than against E7 as determined by the mag-
nitude of response (69–89% against E6 versus 11–31% against E7
at VF1; Fig. 2).
The establishment of memory T cells, normally starting to
form about 4 weeks after immunization, is usually one of the
indispensable factors for protective efﬁcacy of a vaccine29,30.
A relatively high level of IFN-g ELISPOT response was observed
in eight out of nine patients at 24 weeks (VF2) following the last
vaccination, which, when compared with the responses at 8 weeks
(VF1) post vaccination, is decreased for one patient (A03),
comparable for three patients (A01, A06, and A09) and increased
for four patients (A02, A05, A07, and A08; Fig. 2). Overall, this
ﬁnding indicates that GX-188E vaccination-induced E6/E7-
specﬁic memory T-cell response can be maintained for at least
24 weeks post last vaccination. To address whether the IFN-g
response to E6/E7 antigens measured by ELISPOT assay was
generated mainly by T cells and to determine which subset of T
cells played a predominant role, we performed intracellular
cytokine staining (ICS) assays for IFN-g at pre- and post-
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Figure 3 | GX-188E vaccination elicited a signiﬁcant increase in the frequency of HPV16-speciﬁc IFN-cþ CD4 and/or CD8 T cells. Cryopreserved
PBMCs of patients harvested before (VS) and after (VF1) GX-188E vaccination were stimulated with a combined mixture of HPV16 E6 and E7 peptide pools
for 13 h. The frequency of HPV16-speciﬁc IFN-gþ CD4 and CD8 Tcells was determined by ICS followed by multicolour ﬂow cytometry analysis. The gating
strategy used to determine the IFN-g-producing CD4 and CD8 Tcells by ﬂow cytometry (a) and the representative plots and the summary graphs showing
the frequencies of IFN-gþ CD4 (b) and IFN-gþ CD8 (c) Tcells before (VS) and after (VF1) vaccination. Data shown in the graphs represent the average of
two independent experiments, with duplicate in each experiment, and error bars represent s.d. The background values were determined by the response of
the medium only as a control and were r0.004±0.002% for CD4 and r0.003±0.002 for CD8 T cells (mean±s.d.).
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vaccination time points (VS and VF1). As shown in Fig. 3, the
vaccination with GX-188E resulted in an increase in HPV16-
speciﬁc IFN-gþ CD4 T-cell responses in all nine patients, while
IFN-gþ CD8 T-cell response was enhanced in eight out of nine
patients. Thus, with the exception of patient A04, GX-188E
vaccine elicited activation of both HPV16-speciﬁc CD4 and CD8
T cells.
Since persistent HPV infection impairs Th1 cellular response
to HPV, leading to cervical cancer progression11,31–33, we
investigated whether our DNA vaccine could drive the
differentiation of HPV-speciﬁc CD4 T cells into Th1 effector
cells. As expected, the baseline production of common Th1
effector cytokines, such as IFN-g, IL-2 and tumour necrosis
factor-a (TNF-a), before vaccination was remarkably low on
stimulation with E6/E7 peptides. However, the amounts of these
cytokines markedly increased after vaccination in most of the
patients (median 49.9-, 13- and 22.9-fold increases for
IFN-g, IL-2, and TNF-a, respectively; Fig. 4). Consistent with
the IFN-g ELISPOT and ICS data, A08 patient also showed the
greatest increase of Th1 cytokine production. On the other
hand, Th2 (IL-4 and IL-10) and Th17 (IL-17A) cytokines
were not signiﬁcantly increased by vaccination, although patient
A04 had a slightly increased level in production of an
immunosuppressive cytokine, IL-10 (Fig. 4). Taken together
with the above IFN-g ELISPOT and ICS analyses, these results
suggest that GX-188E vaccination leads to the induction of a
strong Th1-polarized HPV-speciﬁc cellular immune response.
GX-188E vaccine-induced CD8 T cells are polyfunctional. To
determine whether GX-188E vaccination induced multiple
aspects of HPV-speciﬁc CD8 T-cell functionality, we assessed the
ability of CD8 T cells, on stimulation with a pool of HPV16 E6
and E7 peptides, to simultaneously express the following ﬁve
different effector functions: cytokines IFN-g, IL-2 and TNF-a, a
chemokine MIP-1b and the cytotoxic activity as determined by
expression of CD107a/b, which is exclusively found during
degranulation of cytotoxic T cells34. When T cells were examined
for two effector functions (IFN-g together with IL-2, TNF-a,
MIP-1b or CD107a/b), we obtained results similar to that
obtained by ICS for only IFN-g. Thus, eight out of nine patients,
with exception of A04, displayed an increase in proportions of
HPV-speciﬁc CD8 T cells with two effector functions after
vaccination (VF1) compared with before vaccination (VS)
(Fig. 5a–d and Supplementary Fig. 2b–e). Examination of all
ﬁve effector functions simultaneously as assessed using Boolean
gating revealed even more striking results. Data on post-
vaccination T cells from the most responsive patient (A08) are
shown as an example in Fig. 5e, and together with the pie chart in
Fig. 5f, shows that 87.6% of HPV16-speciﬁc CD8 T cells were at
least triple-positive and 15% of them had all 5 functions. Similar
analysis in the other six patients (A01, A02, A03, A05, A06 and
A07) revealed that 7.8–46.3% of HPV-speciﬁc CD8 T cells had
three or more functions (Fig. 5f). In contrast, almost all HPV16-
speciﬁc CD8 T cells from patient A09 were not polyfunctional
(Fig. 5f). It is worth noting that Boolean gating analysis could not
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patients except for patient A04 in whom VF1 cells were used, as she received surgery before VF2. The indicated cytokines in the supernatants of cultures
were quantiﬁed using Th1/Th2/Th17 cytometric bead array kit. Shown are mean±s.d. of triplicate. The horizontal dashed line indicates the cutoff
background level determined by standard curve of each cytokine. Mean value of the medium alone background (mean±s.d., pgml 1) was 4.19±0.41 for
IFN-g, 5.11±0.63 for IL-2, 5.58±0.88 for TNF-a, 3.3±0.24 for IL-4, 5.01±0.64 for IL-10 and 5.45±0.28 for IL-17A.
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Figure 5 | GX-188E vaccination induced the polyfunctionality of HPV16-speciﬁc CD8 T cells. Patients’ PBMCs were stimulated at before (VS) and after
(VF1) vaccination as described in Fig. 3 and then analysed with multicolour ﬂow cytometry to detect HPV16-speciﬁc expression of IL-2, IFN-g, TNF-a, MIP-
1b and the cytotoxic degranulating marker, CD107a/b. (a–d) The summary graphs show the frequencies of IFN-gþ CD8 T cells co-expressing IL-2 (a),
TNF-a (b), MIP-1b (c), CD107a/b (d) on gated CD8 Tcells. (e) Representative graph of A08 patient’s polyfunctional responses to HPV16 E6/E7 peptides
subsequent to Boolean gating after vaccination (VF1). The ﬁve functions, CD107a/b, IFN-g, IL-2, MIP-1b and TNF-a are listed along x axis with each of their
respective 31 possible combinations. The ﬁve horizontal bars of different colours below x axis depict the populations of ﬁve, four, three, two or one
functional responses. (f) Each pie chart represents the relative frequency of HPV16 E6/E7-speciﬁc CD8 Tcells with each combination of the ﬁve functional
responses post vaccination (VF1). The numbers to the bottom right of each pie chart indicate the percentage of HPV16-speciﬁc CD8 T cells that produce
three or more functional molecules. The polyfunctional proﬁle of A04 patient was not available because of too low frequency of the responding CD8 Tcells
for analysis. Data shown in the graphs represent the average of two independent experiments, with duplicate in each experiment, and error bars represent
s.d. The background value was determined by the response of the medium only and was 0.0008±0.001% for IFN-gþ IL-2þ , 0.0016±0.0014% for IFN-
gþ TNF-aþ , 0.0015±0.0019% for IFN-gþ MIP-1bþ and 0.0009±0.0012% for IFN-gþ IL-2þ CD8 T cells (mean±s.d.).
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be performed with prevaccination T cells from all patients and
post-vaccination T cells from patient A04 because of extremely
low frequency of responding T cells that displayed effector
function. Overall, these results indicate that GX-188E vaccination
efﬁciently induced generation of polyfunctional HPV-speciﬁc
CD8 T cells in most patients (seven out of nine patients).
It was reported that optimal expansion of responding T cells on
antigen stimulation is essential for providing effective protective
immunity by therapeutic vaccination35,36. Therefore, we
examined the proliferative potential of HPV-speciﬁc CD8 T
cells by stimulating patients’ PBMCs from pre- (VS) and post-
(VF1) vaccination with a pool of HPV16 E6/E7 peptides for 5
days, followed by staining for the expressions of Ki67 and CD38,
which serve as a marker of proliferation and activation,
respectively37,38. PBMCs stimulated with medium alone served
as a negative control to assess antigen speciﬁcity of in vitro-
expanded CD38þKi67þ CD8 T cells. Although one patient
(A01) displayed a relatively high pre-existing proliferative level
prevaccination (VS), the rest of the patients demonstrated low
levels of Ki67þCD38þ CD8 T cells (Fig. 6). After vaccination, all
patients exhibited meaningful improvement in proliferative
activity of HPV-speciﬁc CD8 T cells. In accordance with the
pattern of functional CD8 T cell response (Fig. 5), two patients
(A04 and A09) displayed only a minor increase in proliferating
CD8 T cell population, whereas the other seven patients displayed
a much greater increase of Ki67þCD38þ CD8 T-cell population,
within a range of 3.2- to 21.3-fold increase. Collectively, these
results indicate that GX-188E vaccination in CIN3 patients
substantially augmented both the expansion and polyfunction-
ality of HPV-speciﬁc CD8 T cells.
GX-188E elicits a weak antibody response to E7 protein. When
plasma samples were evaluated for total IgG antibody responses
to E6 and E7 by an end point dilution enzyme-linked immuno-
sorbent assay, all patients had barely detectable or undetectable
IgG titer to both E6 and E7 proteins at baseline (VS;
Supplementary Fig. 3), indicating no meaningful pre-existing E6-
and E7-speciﬁc IgG antibody responses. Interestingly, the anti-
body titres to E6 were not induced in any dose cohort patients
after vaccination. Three out of nine patients (A05, A07, and A09)
generated weak anti-E7 antibody responses following vaccination
with antibody titres ranging from 1:8 to 1:256 (Supplementary
Fig. 3). It is worth noting that T-cell responses to E7 antigens
were generally lower than those against E6 antigens (Fig. 2) and
measurable antibody titres to E7 proteins were not associated
with CD8 T cell responses to E7 antigens.
GX-188E vaccination clears HPV infections and lesions. GX-
188E-induced clinical responses were determined by evaluating
the patients’ HPV infection status as well as the cytological and
histological changes of their high-grade cervical lesions over the
36-week period of the clinical trial (Table 2 and Fig. 1b). At
baseline (VS), all nine patients had CIN3 with either severe
dysplasia (A01, A02, A05, A06, A07 and A08) or carcinoma
in situ (A03, A04 and A09) according to the histological eva-
luation of colposcopic-directed biopsy specimens (Tables 1 and
2). At 8 weeks post last vaccination (VF1), six out of nine patients
were free of lesions—two patients from each cohort (A01 and
A03 from 1mg cohort, A05 and A06 from 2mg cohort, A07 and
A08 from 4mg cohort)—indicating dose independency of the
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Figure 6 | GX-188E vaccination induced proliferation of HPV16-speciﬁc CD8 T cells. Patients’ PBMCs were stimulated at before (VS) and after (VF1)
vaccination and analysed by ﬂow cytometry as described in the Methods to examine the expression of CD38 and Ki67 on virus-speciﬁc CD8 T cells.
(a) Gating strategy to determine the expression Ki67 and CD38 on CD8 T cells by ﬂow cytometry. (b) The representative plots and the summary of data
show the frequency of proliferating CD38þ Ki67þ CD8 Tcells. Data shown in the graph represent the average of two independent experiments. The cells
shown in plots are gated on CD8 T cells. The numbers on the bar graph indicate fold increase post vaccination. The background value was determined by
the response of the medium only control, which was 0.011±0.015% for CD38þ Ki67þ CD8 T cells (mean±s.d.).
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response presumably due to saturation dose at 1mg (Table 2).
Three of these responder patients (A03, A06 and A08) were
negative for the intraepithelial lesion based on cytological analysis
after the second immunization at week 12 (VT4), while three
other patients (A01, A05 and A07) displayed such responses after
the third vaccination at week 20 (VF1) and the last responder
patient (A02) cleared the lesion at the end of the 36-week trial
(VF2). Notably, none of the six early responders displayed any
recurrent cervical dysplasia during the remaining period of the
trial. In cases of two non-responders, patient A04 was treated by
cervical conization at week 24, while patient A09 was monitored
without surgery until the end of study per patient’s request and
remained stable at CIN3 without progressing to invasive carci-
noma. Colposcopic, cytological and histological image analysis
before vaccination (VS) and at the end of the trial (VF2) more
clearly demonstrated the difference in clinical responses to
GX-188E between responders and non-responders, as shown by
the photographs from representative responder A05 and non-
responder A09 patients (Fig. 7).
HPV16 was identiﬁed in the lesions of all nine subjects at the
start of the trial, and one patient (A05) was found to be also
co-infected with HPV18. At week 12 (VT4), four patients (A01,
A03, A06 and A08) and patient A05 showed clearance of HPV16
and HPV18 viruses, respectively (Table 2), indicating viral
clearance after the second immunization. At week 20 (VF1),
HPV DNAs in cervical lesions were cleared in six out of nine
patients (A01, A03, A05, A06, A07 and A08) and one more
patient (A02) cleared the virus at week 36 (VF2). Since these
seven patients also cleared their lesions with the identical kinetics,
there was perfect correlation between the clinical and virological
responses (Table 2). Beside HPV16 and HPV18, two patients
(A06 and A07) were found to be co-infected with other high-risk
common types of HPV at baseline (VS). In addition, one patient
(A05) became infected with the common HPV type in the midst
of the trial (VT4). In contrast to A07 patient, A05 and A06
patients cleared co-infected common types of HPV at VF2 and
VT4, respectively, presumably due to a bystander effect caused by
the elimination of HPV16-infected intraepithelial neoplastic cells.
It is notable that the three patients (A03, A06 and A08) who
cleared their lesions and HPV infection at the early time point
(VT4) promptly displayed a relatively high magnitude of HPV-
speciﬁc polyfunctional CD8 T-cell response (Table 2 and Fig. 5).
In addition, the other four patients (A01, A02, A05 and A07) with
a meaningful polyfunctional CD8 T-cell response exhibited the
complete resolutions of their lesions and HPV infections after the
third vaccination either at week 20 (VF1) or at the end of the trial
(VF2; Table 2 and Fig. 5). In contrast, two non-responder patients
(A04 and A09) had almost no polyfunctional CD8 T-cell
response. The correlation between the induction of polyfunc-
tional T-cell response and clinical outcome is readily apparent
when the individual data from the patients were grouped into
non-responders (A04 and A09) and responders (A01, A02, A03,
A05, A06, A07 and A08) to generate the polyfunctional proﬁle
with three or more functions (Supplementary Fig. 4). Hence, our
results indicate that the clinical efﬁcacy of GX-188E vaccine
strongly correlates with the extent of systemic HPV-speciﬁc
polyfunctional CD8 T-cell response. Overall, GX-188E vaccina-
tion led to the clinically and virologically meaningful complete
response rate of 78% (seven out of nine patients) (Table 2).
Discussion
In this study, we have demonstrated the efﬁcacy of a novel HPV
E6/E7 DNA therapeutic vaccine, designated GX-188, strategically
designed to induce robust type 1 T cell-mediated immunity and
to eradicate HPV infection-associated lesions. So far, several types
of HPV therapeutic vaccines have been evaluated in patients
diagnosed with CIN2/3 lesions using viral vectors13,14, peptides15,
proteins16 or plasmid DNA17. In contrast to these previous
studies that performed excision surgery at weeks 9–15 after
vaccination, preventing extended observation of histological
change, our current trial was designed to assess the clinical
outcomes and immune responses at 20 and/or 36 weeks after the
ﬁrst vaccination to investigate the kinetics of immune response
and the durability of vaccine efﬁcacy. In this study, viral clearance
(four out of nine patients) and cytological recovery (three out of
nine patients) were already apparent at week 12 and most of the
complete responders (six out of seven patients) cleared the
cervical lesions within week 20 post vaccination with durable
immunity, that is, without any recurrence of cervical dysplasia or
re-emergence of HPV infection during the remaining 16 weeks
period of the clinical trial. Collectively, compared with the
Table 2 | Virological and clinical responses during and after immunization with GX-188 DNA vaccine by electroporation.
Patient
no.
Dose At week 0 (VT1) At week 12 (VT4) At week 20 (VF1) At week 36 (VF2)
HPV
status*
Cytology Histology HPV
status*
Cytology HPV
status*
Cytology Histology HPV status* Cytology Histology
A01 1mg 16 ASC-H CIN3 Negative ASC-US Negative NIL Normal Negative NIL Normal
A02 1mg 16 HSIL CIN3 16 HSIL 16 HSIL CIN3 Negative NIL Normal
A03 1mg 16 HSIL CIN3 Negative NIL Negative NIL Normal Negative NIL Normal
A04 2mg 16 HSIL CIN3 16 HSIL 16 HSIL CIN3 NDw NDw NDw
A05 2mg 16 and 18 HSIL CIN3 16 and
common
ASC-US Negative,
common
NIL Normal Negative NIL Normal
A06 2mg 16 and
common
ASC-H CIN3 Negative NIL Negative NIL Normal Negative NIL Normal
A07 4mg 16 and
common
HSIL CIN3 16 and
common
ASC-US Negative,
common
NIL Normal Negativez,
common
NILz Normalz
A08 4mg 16 ASC-US CIN3 Negative NIL Negative NIL Normal Negative NIL Normal
A09 4mg 16 HSIL CIN3 16 HSIL 16 HSIL CIN3 16 HSIL CIN3
ASC-H, atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion; ASC-US, atypical squamous cells of undetermined signiﬁcance; CIN3, cervical intraepithelial neoplasia 3;
HPV, human papilloma virus; HSIL, high-grade squamous intraepithelial lesion; NIL, no intraepithelial lesion.
*PCR results for the detection of HPV (Negative, both HPV 16 and 18 negative; 16, HPV 16 positive; Common, other high-risk HPV 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and/or
82 positive).
wNot done. A04 patient were treated by cervical conization at week 24.
zA07 patient has visited and undergone examinations for colposcopy and cervical biopsy at week 42 instead of week 36 due to her personal situations.
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previous reports, our results appear to be highly novel and
clinically meaningful for the following reasons: ﬁrst, the EP-
delivered GX-188 elicited the relatively high and durable HPV-
speciﬁc Th1-polarized cellular immune responses in eight out of
nine CIN3 patients with severe dysplasia or carcinoma in situ,
and seven out of nine patients (78%) had complete regression of
their high-grade lesion and clearance of HPV DNA, which are the
highest response rate compared with the previous reports in
clinical trials of HPV vaccines. Second, cytological, histological
and virological evaluations yielded the same results in the
responders, indicating induction of a complete response by GX-
188E. Third, the normalization of lesions by GX-188E vaccination
was maintained without recurrence of dysplasia during the entire
study period of 36 weeks, indicating a sustained therapeutic
efﬁcacy of the vaccine. Finally, clinical and virological responses
at the cervix were correlated with the magnitude of the
polyfunctional CD8 T-cell response in the blood, suggesting
that systemic HPV-speciﬁc CD8 T-cell responses might serve as a
predictive biomarker for determining clinical outcomes of
therapeutic vaccine in the setting of high-grade cervical lesions.
It has been reported that regression of CIN2/3 can occur
spontaneously in some patients at a rate ranging from 11 to 30%
over Z1 year to 38% between 9 and 20 weeks after colposcopic
biopsy39–41. Even when considered in light of these reports, our
ﬁnding of complete regression in six out of nine patients (67%) at
20 weeks and in seven out of nine patients (78%) at 36 weeks after
GX-188E vaccination indicates that vaccine-induced immunity is
considerably more effective than natural immunity. However, we
cannot rule out the possibility that some of the responders,
especially the ones who have responded early, would have
spontaneously cleared their lesions. A corollary to this possibility
is that the vaccine-induced response rate beyond the maximum
rate of spontaneous regression is in the same ballpark as that of
landmark vaccine trial in which a synthetic long-peptide
vaccination exhibited 47% of complete response rate in patients
with another HPV-associated lower genital dysplasia, vulvar
intraepithelial neoplasia 3 (ref. 19).
The induction of strong HPV-speciﬁc Th1 and CD8 T-cell
immunity by GX-188E vaccination leading to complete clearance
of HPV DNA and high-grade cervical lesions observed in this
study is likely due to the following reasons: codon optimization of
HPV E6/E7 genes42, intracellular targeting of expressed E6/E7
antigens to secretion pathway by the fused tpa signal sequence43,
enhanced DNA vaccine delivery by EP44 and the utilization of a
high-expression vector45. In addition, since mutations or
deletions of the E6/E7 sequence motifs crucial for binding to
p53 and pRb could result in loss of their T cell-recognizing
epitopes17,18, we instead genetically engineered HPV E6 and E7
genes by shufﬂing N- and C-terminal domains, with an
overlapping region, to maintain T-cell epitopes, while
abrogating the oncogenic potential of these proteins. Finally,
the Flt3L gene was fused to engineered E6/E7 genes as a built-in
Non-responder
(A09)
Responder
(A05)
VS
VF2
VF2
VF2
VS
VS
Figure 7 | GX-188E vaccination led to the clearance of cervical lesions as
determined by colposcopy, cytology and histology. Photographs of
cervical colposcopy (a), endocervical cytology (b) and histology (c) from a
representative responder (A05) and a non-responder (A09) patient before
(VS) and after (VF2) GX-188E immunization are shown. (a) Patient A05 at
VS exhibited dense acetowhite epithelium with coarse punctuation in
transformation zone, but at VF2 showed reduced intermediate acetowhite
epithelium without punctuation; patient A09 at VS and VF2 displayed
dense acetowhite epithelium with rolled margin and coarse punctuation in
transformation zone. Colposcopic pictures of the cervix at  6
magniﬁcation were taken. The white bars are used to prevent the disclosure
of patients’ information. (b) Patient A05 at VS exhibited high-grade
squamous intraepithelial lesion (HSIL) with enlarged nuclear size and
hyperchromasia, but at VF2 showed only normochromic epithelium with no
intraepithelial lesion (NIL). Scale bars, 10mm; patient A09 at VS and VF2
displayed HSIL variable nuclear size and hyperchromasia. Scale bars, 5 mm.
(c) Patient A05 at VS was diagnosed as CIN3 with full thickness of the
epithelium, and with mitoses visible in the upper layer, but at VF2 displayed
normal squamous epithelium without atypical neoplastic cells. Scale bars,
40mm; patient A09 at VS and VF2 was diagnosed as CIN3 with thick and
abnormal epithelium and the presence of keratinized cells with nuclear
atypical in the upper layer. Scale bars, 20mm.
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genetic adjuvant, since Flt3L is known to induce Th1 immune
responses through preferential expansion of CD8aþ lymphoid
DCs46–49. It was reported that bone marrow-derived DCs pulsed
with cell lysates containing Flt3L-E7 fusion protein presented E7
antigens through the major histocompatibility complex class I
pathway more efﬁciently than those pulsed with wild-type E7
protein50, indicating a potential role of Flt3L in facilitating cross-
priming. Moreover, Flt3L-fused DNA vaccine elicited the highest
antigen-speciﬁc IFN-g-secreting T-cell responses compared with
other molecules for targeting antigens to DCs, such as CD40L and
ﬂagellin43,51. In contrast to T-cell responses, GX-188E
vaccination induced the mild increase of IgG titres against only
E7 protein in three out of nine patients (A05, A07 and A09;
Supplementary Fig. 2). These weak antibody responses can be
explained by the feature of GX-188 DNA vaccine in which Flt3L-
mediated Th1-polarization may inhibit Th2-type responses and
antibody production by cross-regulation of Th1/Th2 responses52.
Since persistent HPV infection is known to promote Th2
response, thereby leading to poor T-cell immunity and
continual progression of lesion11,31,32, our strategy to
incorporate Flt3L to HPV DNA vaccine antigen may be an
effective approach for inducing Th1-polarized cellular immunity.
The immunological and clinical outcomes after vaccination are
generally variable and may be determined in part by host genetic
factors. In the present study, GX-188E vaccine achieved complete
response in seven out of nine patients (78%). Among seven
responders, six patients carrying human leukocyte antigens
(HLA)-A*02 exhibited high polyfunctional CD8 T-cell responses
as well as complete regression of CIN3 (Table 1). Among the two
non-responders, patient A04 with HLA-A*26 and -A*30 did not
induce HPV-speciﬁc CD8 T-cell responses at all. It was reported
that 5–15% of vaccine failed to seroconvert by the standard
hepatitis B vaccination schedule and this was found to be
associated with speciﬁc HLA alleles53. In this regard, it will be of
interest to investigate whether speciﬁc HLA alleles can be a
contributing factor for the impaired induction of HPV-speciﬁc
CD8 T-cell response by GX-188E vaccination.
The other non-responder patient (A09) exhibited a comparable
magnitude of antigen-speciﬁc CD8 T-cell response with two
effector functions, but had lower polyfunctional proﬁle of CD8 T
cells with three or more effector functions than responder
patients, indicating that the polyfunctionality of vaccine-induced
CD8 T cells may contribute to clinical outcomes. It is worth
noting that the patient A09, who was infected with only HPV16,
displayed a higher T-cell response to HPV18 than to HPV16 in
IFN-g ELISPOT assay. Thus, this biased response towards
HPV18 in the patient A09 may have led to the impaired
HPV16-speciﬁc polyfunctional CD8 T-cell response. Alterna-
tively, it is possible that local immunity at cervix could be
involved in the clearance of lesions. Recently, combined
vaccination with a heterologous DNA prime-recombinant
vaccinia vector-based boost regimen induced a tissue-localized
T-cell response in most patients with CIN2/3, which was
suggested to be informative for determining vaccine efﬁcacy54.
In our current trial, complete clearance of lesions was already
achieved at the ﬁrst biopsy after vaccination (at week 20) in most
patients, and thus we could not obtain the lesions to assess
vaccine-induced local immunity. To address this issue, we are
planning to take a biopsy at an earlier time point (week 6–8 after
ﬁrst vaccination) in upcoming phase 2 clinical trial. Finally,
patient A09 had the largest lesion size with carcinoma in situ,
probably providing more severe immunosuppressive
microenvironment by which the effector function of vaccine-
induced systemic CD8 T cells could be thwarted. It was reported
that median cell density of stromal Foxp3þ regulatory T cells
expressing IL-10 and indoleamine 2, 3-dioxygenase appear to
increase signiﬁcantly in the cervix with increasing pathology and
cancer55. Thus, it would be important to develop strategies to
neutralize these immunosuppressive factors and/or enhance the
vaccine-induced T-cell responses to improve the clinical efﬁcacy
of DNA vaccines in patients with larger lesions and cancer.
Among three CIN3 patients with carcinoma in situ, one patient
(A03) who had a relatively high pre-existing HPV-speciﬁc cellular
immune response completely cleared both HPV infection and the
high-grade lesions on GX-188E vaccination. Thus, it would be of
interest to investigate whether the pre-existing cellular immunity
could be an indicator of the clinical outcome of therapeutic
vaccine in CIN3 patients with carcinoma in situ. Most
importantly, all six CIN3 patients with severe dysplasia showed
eradication of HPV DNA and regression of their lesion following
GX-188E DNA vaccination. Even though the number of patients
(n¼ 9) is too small to draw a deﬁnite conclusion, our ﬁndings
may provide an important insight into the key requirements for a
therapeutic vaccine to be effective against various persistent
infections and chronic diseases. Considering that the current
primary treatment option for CIN3 is surgical excision, which is
often accompanied with several side effects8, our non-invasive
immunological approach with good safety and excellent clinical
efﬁcacy within 12 to 36 weeks could mark one of important
milestones for treating CIN3 patients with severe dysplasia or
carcinoma in situ.
Methods
Ethics statement. The clinical trial protocol was reviewed and approved by the
Institutional Review Board at Cheil General Hospital and Women’s Healthcare
Center (CGH-IRB-2012-35). This study was conducted in accordance with the
ethical principles that had their origin in the current Declaration of Helsinki and
was consistent with International Conference on Harmonization Good Clinical
Practice (IHC GCP) and applicable regulatory requirements. All study participants
gave written informed consent before undergoing screening for study eligibility and
enrolment. This trial is listed at http://www.clinicaltrials.gov (NCT01634503)
Study design and patients. This phase 1 clinical study was conducted as an open
label, single center, dose-escalation study at Cheil General Hospital & Women’s
Healthcare Center, Seoul, Korea. The primary end point was to evaluate safety and
tolerability in patients with CIN3. The secondary end points included systemic
induction of HPV E6- and E7- speciﬁc T-cell immune responses measured by IFN-
g ELISPOT, and changes of involved lesions and HPV infection status at the
uterine cervix. Women aged between 20 and 50 years with histologically and
virologically proven HPV16- or HPV18-associated CIN3 were enroled in the study.
The CIN3 was conﬁrmed by colposcopy-directed biopsy and HPV16 or HPV18
positivity was determined by PCR. Subjects with hepatitis B virus, hepatitis C virus
or human immunodeﬁciency virus infections, abnormal electrocardiography
including arrhythmia, history of severe adverse drug events or severe allergic dis-
eases were excluded. Females who were pregnant or planning to be pregnant were
not recruited in the study. Vaccination consisted of a series of three vaccine
injections administered intramuscularly to alternating deltoid muscles at weeks 0, 4
and 12. A standard 3þ 3 dose-escalation scheme was followed and dose levels of 1,
2 and 4mg were tested. At the highest dose, 4mg of GX-188E was split into
2þ 2mg and injected to the left and right deltoids muscles. For the intramuscular
injector, an EP device (TriGrid Delivery System, Ichor medical systems, Inc.) was
used to facilitate DNA uptake into cells.
HLA typing. HLA typing was accomplished at Catholic Hematopoietic Stem Cell
Bank, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Sequence-based typing (SBT) of HLA was performed by heterozygous ampliﬁca-
tion followed by sequencing of the complete exons 2, 3 of HLA-A and -B. For
locus-speciﬁc ampliﬁcation, primers were used in in-house method. After appli-
cation by PCR, agarose gel electrophoresis of the PCR products was conducted to
assess the quantity and quality. Cycle sequencing reactions using the ABI PRISM
BigDye terminator kit (Applied Biosystems, CA, USA) and the automated ABI377
DNA Sequencer (Applied Biosystems, CA, USA) were performed. These data were
analysed by using SBT analysis programme (Conexio Genomics, Assign SBT
v3.5.1).
DNA vaccine. The study vaccine, pGX-188, contains a plasmid DNA encoding E6
and E7 proteins of HPV serotypes 16 and 18 fused with tpa signal sequence and
extracellular domain of Flt3L. Synthetic codon-optimized E6 or E7 genes were
fragmented into two parts (C-terminal and N-terminal regions) with a small
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overlapping sequence (encoding 16 amino acids), and shufﬂed as shown in Fig. 1a.
The fused DNA sequences including tpa, Flt3L and shufﬂed E6/E7 genes were
inserted in high-expression vector, pGX27 (ref. 45), to generate GX-188, which was
produced in E. coli DH5a under cGMP condition at Althea Technologies, Inc., San
Diego, CA.
Virological and clinical responses. The assessments including colposcopy, his-
tology, endocervical cytology and HPV genotyping test were conducted by local
laboratory at the trial site. The assessments were performed in compliance with the
standardized method or the internal protocol of Cheil General Hospital and
Women’s Healthcare Center. Responses to treatment were evaluated using virology
and histology results at weeks 20 and 36 post GX-188E vaccination.
For histological evaluation, biopsy samples were taken during screening and
two follow-up visits at weeks 20 and 36. Samples were ﬁxed with 10%
formaldehyde and 4–5 mm sections were stained with haematoxylin and eosin.
Endocervical samples were collected using cytobrush (Cytyc Corp., Boxborough,
MA) during colposcopic examination. This endocervical cytology test was also used
in addition to histology for the assessment of GX-188E vaccination. Data from
histological and cytological analyses were reviewed independently by at least two
pathologists and results were conﬁrmed after discussion with by conference of all
pathologists and investigators.
To evaluate virological response, HPV typing was performed to determine
whether subjects were infected by either HPV16 and/or HPV18. Samples were
collected from the cervix by using a swab-type device, and total DNAs were
extracted using the AccuPrep Genomic DNA Extraction kit (Bioneer Com. Seoul,
Korea). HPV detection and genotyping was done by Multiplex-PCR system using
the IVD CE marked Seeplex HPV4A ACE Screening kit (Seegene Inc., Seoul,
Korea) according to the manufacture’s protocol. The Seeplex HPV4A ACE
Screening kit can identify HPV16, HPV18, other high-risk types (High risk
common: 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and/or 82), HPV6
and HPV11 types at the same time. PCR products were analysed using an
automatic MultiNA instrument (Shimadzu Co., Tokyo, Japan). HPV DNA
genotyping was double checked in cervical cells using Cheil HPV DNA Chip with
real time PCR to compensate the accuracy of HPV genotype as previously
described56.
Ex vivo IFN-c ELISPOT. Cryopreserved and thawed PBMCs were adapted with
OpTmizer CTS medium (Life Technologies) for more than 6 h at 37 C, 5% CO2,
and subsequently PBMCs (2 105 cells per well) were stimulated with 2 mgml 1
of four different pools of HPV16 and HPV18 E6- or E7-derived peptides (20-mer
with 10 amino acids overlapping) for 48 h. Phytohaemagglutinin and the medium
only served as positive and negative controls, respectively. After stimulation, spots
indicating IFN-g-secreting cells were developed according to manufacturer’s
instructions (BD Bioscience). The number of spots was analysed with an auto-
mated ImmunoSpot Analyzer (Cellular Technology Ltd.). The HPV-speciﬁc
responses were calculated by subtracting the mean number of spots in the medium
only control from the mean number of spots in experimental wells, which were
expressed as SFUs per 106 PBMCs57. The assay was performed in triplicate, and the
background number of spots was 5.7±2.2 (mean±s.d.). Antigen-speciﬁc T-cell
responses were considered to be positive when the mean number of spots in the
well with the antigen was threefold higher than that of the well with medium
control58. In addition, a post-analysed vaccine-induced response was deﬁned as
positive when at least a threefold increase in T-cell frequency was observed after
vaccination compared to before vaccination15.
ICS. Cryopreserved and thawed PBMCs were resuspended in OpTimizer CTS, and
rested for more than 6 h at 37 C, 5% CO2. PBMCs were plated in duplicate and
stimulated with a combined mixture of HPV16 E6 and E7 peptides in one pool (15-
mer with eight amino acids overlapping) at a concentration 2 mgml 1, a-CD3
(positive control, 10mgml 1, UCHT1, BD Bioscience) or the medium alone
(negative control) in the presence of 1 mgml 1 of a-CD28 (L293, BD Bioscience)
and a-CD49d (L25, BD Bioscience) for 13 h. Secretion inhibitors (monensin/bre-
feldin A, BD Bioscience) were added 90min after initial stimulation. After sti-
mulation, cells were washed with PBS for subsequent immunostaining and
polychromatic ﬂow cytometric analysis. Antibodies for staining cells were CD19-
APCCy7 (5ml per test, HIB19, Biolegend), CD4-PerCPCy5.5 (5 ml per test, RPA-
T4, Biolegend), CD8-PECy7 (5 ml per test, RPA-T8, BD Bioscience), CD3-BV605
(Bright Violet 605) (5 ml per test, UCHT1, Biolegend), CD3-BV500 (5 ml per test,
UCHT1, BD Horizon), Live/dead-APCCy7 (0.5 ml per test, Life technologies), MIP-
1b-PE (0.5 ml per test, D21-1351, BD Bioscience), IFN-g-APC (5 ml per test, 4S.B3,
Biolegend), TNF-a-BV421 (5ml per test, MAb11, Biolegend), IL-2-BV711 (5 ml per
test, 5344.111, BD Horizon), CD107a-FITC (5 ml per test, H4A3, BD Bioscience)
and CD107b-FITC (5ml per test, H4B4, BD Bioscience). Fluorescence-activated cell
sorting analysis was accomplished by Fortessa ﬂow cytomer (BD Bioscience), and
the data were analysed using FlowJo software (Tree Star). Boolean gating was used
to determine simultaneous cytokine production from CD8 T cells. Analysis of
polyfunctionality was performed with SPICE59. A positive response was deﬁned as
detecting at least twice the percentage of cytokine-producing T cells than in the
medium only control, and the response should be visible as a clearly distinguishable
population of cytokine-producing cells separated from the nonproducing cells. A
post-analysed vaccine-induced response was deﬁned as detecting at least a
threefold increase in the percentage of antigen-speciﬁc cytokine-producing T cells
than that at prevaccination60.
Cytokine proﬁle analysis by cytometric bead array. Cryopreserved and thawed
PBMCs (2 105 per well) were resuspended in OpTimizer CTS, and rested for
more than 6 h at 37 C, 5% CO2, and subsequently PBMCs were plated in duplicate
and were stimulated in RPMI 1,640 containing 10% fetal bovine serum,
100Uml 1 penicillin and 100mgml 1 streptomycin with a combined mixture of
HPV16 E6 and E7 peptides in one pool (15-mer with eight amino acids over-
lapping) at a concentration of 2 mgml 1 or the medium only as negative control in
96-well plates. Culture supernatants were harvested 48 h after the stimulation and
cytokines were quantitated by Th1/Th2/Th17 cytometric bead array (CBA) kit
(BD Biosciences). According to manufacturer’s instructions, the proposed
detection limit was 2.5–5 pgml 1 (IL-2, IL-4, IL-10, TNF-a and IFN-g) or
19 pgml 1 (IL-17A), and the cutoff value was set at 5 pgml 1 because the
standard curve of each cytokine showed linearity starting at this concentration
(Supplementary Fig. 5). Positive antigen-speciﬁc reaction was deﬁned as a cytokine
concentration above the cutoff value and 42 the concentration of the medium
control60. A post-analysed vaccine-induced response was deﬁned as being at least
threefold higher in the cytokine production than that at prevaccination60.
Proliferation assay. Cryopreserved and thawed PBMCs (1 106 cells per well)
were adapted with OpTmizer CTS medium (Life technologies) for more than 6 h at
37 C, 5% CO2. PBMCs were plated and stimulated with a combined mixture of
HPV16 E6 and E7 peptides in one pool (15-mer with eight amino acids over-
lapping) at a concentration 2 mgml 1 in RPMI 1,640 containing 10% fetal bovine
serum, 100Uml 1 penicillin and 100 mgml 1 streptomycin for 5 days. a-CD3
mAb and the medium alone served as positive and negative controls, respectively.
After 3 days, cell cultures were replaced with 100ml of fresh medium. At the end of
culture, cells were washed with PBS for subsequent immunostaining and poly-
chromatic ﬂow cytometric analysis. The cells were stained with CD19-FITC (5 ml
per test, HIB19, Biolegend), CD4-PerCPCy5.5, CD8-PECy7, CD38-BV421 (5 ml per
test, HIT2, BD Bioscience), CD3-BV605, Ki-67-PE (20 ml per test, B56, BD
Bioscience), and Live/Dead-APCCy7. Responses at least threefold greater than
those of the medium control were considered to be positive. A post-analysed
vaccine-induced response was deﬁned as being at least threefold higher in the
percentage of antigen-speciﬁc proliferating CD8 T cells than that at prevaccination.
Statistical analysis. Descriptive statistics of the safety, pharmacodynamics and
pharmacokinetic outcomes was performed using SAS (V9.1) software. Standard
and two-tailed paired Student’s t-test was performed to analyse statistical sig-
niﬁcance of all quantitative data using Prism 5.0 software (GraphPad).
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